



Date 23 October

Sydney, Australia

## ASX: NOX

### Noxopharm Limited

ABN 50 608 966 123

#### Registered Office:

Suite 1 Level 6  
50 Queen St  
Melbourne VIC 3000  
Australia

#### Operations Office:

Suite 3, Level 4  
828 Pacific Highway  
Gordon NSW 2072  
Australia

#### Board of Directors

##### Mr Peter Marks

Chairman  
Non-Executive  
Director

##### Dr Graham Kelly

Chief Executive Officer  
Managing Director

##### Dr Ian Dixon

Non-Executive  
Director

## UPDATE – GENERAL MEETING AGENDA

Noxopharm Ltd will be holding a General Meeting on Monday 6<sup>th</sup> November 2017 for shareholders to consider 2 resolutions in relation to the formation of a subsidiary company, Nyrada, Inc.

Meeting agenda:

**10.00 – 10.15. Opening remarks.** *Dr Graham Kelly, Noxopharm Managing Director.*

**10.15 – 10.45. General Meeting.**

**10.45 – 11.10. NYX-104 program and stroke.** *Professor Gary Housley, Chair of Physiology and Director, Translational Neuroscience Facility, School of Medical Sciences, UNSW Sydney.*

**11.10 – 11.20. NYX-205 program and peripheral neuropathy.** *Dr Benny Evison, Noxopharm Non-Oncology Program Director.*

**11.20 – 11.40. Beyond statins.** *Dr Ian Dixon, Noxopharm Non-Executive Director.*

**11.40 – 12.00. Discussion.**

**Venue:** Company's offices

Suite 3 Level 4  
828 Pacific Highway Gordon NSW 2072

**Access:** The offices are located 300 m from Gordon Railway Station. Parking is available in Gordon Centre Shopping Mall (802 Pacific Highway).

**RSVP:** For organisational purposes, please indicate your intention to attend:  
[info@noxopharm.com](mailto:info@noxopharm.com)

#### About Noxopharm

Noxopharm is a clinical-stage, Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of drug- and radio-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.

#### Investor & Corporate Enquiries:

Prue Kelly  
M: 0459 022 445  
E: [info@noxopharm.com](mailto:info@noxopharm.com)

#### Company Secretary :

David Franks  
T: +61 2 9299 9690  
E: [dfranks@fa.com.au](mailto:dfranks@fa.com.au)

[www.noxopharm.com](http://www.noxopharm.com)